

SECURITIES AND EXCHANGE COMMISSION

SEC FORM 17-C

CURRENT REPORT UNDER SECTION 17 OF THE SECURITIES REGULATIONS CODE (SRC) AND SRC RULE 17(a)-1(b)(3) THEREUNDER

1. **December 21, 2023**
Date of Report (Date of earliest event reported)
2. **34218** SEC Identification Number
3. **000-153-610-000** BIR Tax Identification Number
4. **AYALA CORPORATION**
Exact Name of registrant as specified in its charter
5. **PHILIPPINES** Province, country or other jurisdiction of incorporation
6. (SEC Use Only)
Industry Classification Code
7. **37F to 39F, Ayala Triangle Gardens Tower 2, Paseo de Roxas
cor Makati Avenue, Makati City** Address of principal office
- 1226** Postal code
8. **(02)7908-3000**
Registrant's telephone number, including area code
9. **N/A**
Former name or former address, if changed since last report
10. Securities registered pursuant to Sections 4 and 8 of the SRC

Title of Each Class	Number of Shares of Common Stock Outstanding and Amount of Debt Outstanding
Common Shares	619,805,425 shares
Preferred A Shares (Reissued)	5,244,515
Preferred B Series 2 Shares	30,000,000 shares
Voting Preferred Shares	200,000,000 shares

: **Item 9- Other Events**

Re: Press Release – AC Health strengthens pharma footprint through investment in St. Joseph Drug

Pursuant to the requirements of the Securities Regulations Code, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AYALA CORPORATION

Registrant



Jose Martin C. Lopez

Head – Investor Relations

Date : **December 21, 2023**

* Print name and title of the signing officer under the signature.



33F Tower One, Ayala Triangle, Ayala Avenue
Makati City, 1226 Philippines
www.ayala.com.ph

December 21, 2023

Securities and Exchange Commission

17/F SEC Headquarters, 7907 Makati Avenue
Barangay Bel-Air, Makati City

Attention: **Director Vicente Graciano P. Felizmenio, Jr.**
Director, Markets and Securities Regulation Department

Philippine Stock Exchange

6/F PSE Tower
5th Avenue corner 28th Street,
Bonifacio Global City, Taguig City

Attention: **Ms. Alexandra D. Tom Wong**
Officer-In-Charge, Disclosure Department

Philippine Dealing and Exchange Corporation

29/F BDO Equitable Tower
8751 Paseo de Roxas, Makati City

Attention: **Atty. Marie Rose M. Magallen-Lirio**
Head, Issuer Compliance and Disclosure Department

Mesdames/Gentlemen:

Please be informed that on December 21, 2023, Ayala disclosed a press release in relation to its wholly-owned subsidiary, Ayala Healthcare Holdings, Inc. (AC Health), acquiring a significant minority stake in North Luzon-based pharmaceutical company, St. Joseph Drug. The definitive agreements were signed last December 15 between St. Joseph Drug and AC Health's pharmaceutical arm, AHCHI Pharma Ventures Inc.

Please see attached press release for more information.

Very Truly Yours,

Jose Martin C. Lopez
Head - Investor Relations

SECURITIES AND EXCHANGE COMMISSION

SEC FORM 17-C

CURRENT REPORT UNDER SECTION 17 OF THE SECURITIES REGULATION CODE AND SRC RULE 17.2(c) THEREUNDER

1. Date of Report (Date of earliest event reported)
Dec 21, 2023
2. SEC Identification Number
34218
3. BIR Tax Identification No.
000-153-610-000
4. Exact name of issuer as specified in its charter
AYALA CORPORATION
5. Province, country or other jurisdiction of incorporation
PHILIPPINES
6. Industry Classification Code(SEC Use Only)
7. Address of principal office
37F to 39F, Ayala Triangle Gardens Tower 2, Paseo de Roxas cor Makati Avenue, Makati
City
Postal Code
1226
8. Issuer's telephone number, including area code
(02) 7908-3000
9. Former name or former address, if changed since last report
NA
10. Securities registered pursuant to Sections 8 and 12 of the SRC or Sections 4 and 8 of the RSA

Title of Each Class	Number of Shares of Common Stock Outstanding and Amount of Debt Outstanding
Common Shares	619,807,425
Preferred A Shares (Reissued)	5,244,515
Preferred B Series 2 Shares	30,000,000
Voting Preferred Shares	200,000,000

11. Indicate the item numbers reported herein
Item 9

The Exchange does not warrant and holds no responsibility for the veracity of the facts and representations contained in all corporate disclosures, including financial reports. All data contained herein are prepared and submitted by the disclosing party to the Exchange, and are disseminated solely for purposes of information. Any questions on the data contained herein should be addressed directly to the Corporate Information Officer of the disclosing party.



Ayala Corporation AC

PSE Disclosure Form 4-31 - Press Release
References: SRC Rule 17 (SEC Form 17-C)
Section 4.4 of the Revised Disclosure Rules

Subject of the Disclosure

AC Health strengthens pharma footprint through investment in St. Joseph Drug

Background/Description of the Disclosure

Ayala's wholly-owned subsidiary, Ayala Healthcare Holdings, Inc. (AC Health) has acquired a significant minority stake in North Luzon-based pharmaceutical company, St. Joseph Drug (Joleco Resources, Inc.). The definitive agreements were signed last December 15 between St. Joseph Drug and AC Health's pharmaceutical arm, AHCHI Pharma Ventures Inc. (APV).

APV serves as the holding company for AC Health's pharmaceutical businesses. Composed of Generika Drugstore, the pioneer in generic retail pharmacies, and I.E. Medica and MedEthix, its pharma importation and distribution arms, APV now includes St. Joseph Drug. This strategic acquisition enables AC Health to strengthen its pharma footprint and reach more Filipinos throughout the country.

Other Relevant Information

Please see attached press release.

AC Health strengthens pharma footprint through investment in St. Joseph Drug

Manila, Philippines, December 21, 2023 – Ayala Healthcare Holdings, Inc. (AC Health) has acquired a significant minority stake in North Luzon-based pharmaceutical company, St. Joseph Drug (Joleco Resources, Inc.). The definitive agreements were signed last December 15 between St. Joseph Drug and AC Health’s pharmaceutical arm, AHCHI Pharma Ventures Inc. (APV).



IN PHOTO (L to R): Anthony L. Cruz (Director – St. Joseph Drug); Maria Eleanor L. Cruz-Valero (Corporate Secretary – St. Joseph Drug); Atty. Yet Abarca (President and CEO – APV and Generika Drugstore); Paolo Borromeo (President and CEO – AC Health); Ma. Socorro Dorotea “Gigi” L. Cruz (Chairman, President, and CEO – St. Joseph Drug); Marilene L. Cruz-Bernal (Treasurer and COO – St. Joseph Drug); Maria Catherine L. Cruz-Bangsal (Director – St. Joseph Drug); Joselito L. Cruz (Director – St. Joseph Drug)

Established in 1958 by pharmacist Jose “Pepe” Cruz and his wife Leila Lagman from Dagupan City, St. Joseph Drug has grown from a modest provincial drugstore with three employees and a 3.5-meter storefront into a leading regional pharmaceutical chain spanning over 112 stores across Northern Luzon.

"The addition of St. Joseph Drug to our portfolio is in line with our commitment to enhance accessibility and affordability of healthcare for Filipinos nationwide. St. Joseph Drug, alongside our existing retail pharma brand, Generika Drugstore, will expand our capacity and footprint to distribute quality and affordable medicine to our countrymen. Together with our pharma importation businesses IE Medica and MedEthix, we will greatly enhance synergies and efficiencies within our pharmacy platform to further improve our products and services throughout our AC Health network," said Paolo Borromeo, President and CEO of AC Health.

Ma. Socorro Dorotea “Gigi” L. Cruz, Chairman, President, and CEO of, St. Joseph Drug also expressed enthusiasm about the partnership, stating, "This partnership with AC Health marks a significant milestone in St. Joseph Drug’s journey. We are proud to have established

St. Joseph Drug as a household name in Northern Luzon over the years, and we look forward to broadening our reach with AC Health.”

AHCHI Pharma Ventures Inc. (APV) serves as the holding company for AC Health's pharmaceutical businesses. Composed of Generika Drugstore, the pioneer in generic retail pharmacies, and I.E. Medica and MedEthix, its pharma importation and distribution arms, APV now includes St. Joseph Drug. This strategic acquisition enables AC Health to strengthen its pharma footprint and reach more Filipinos throughout the country.

@@@

AC Health

Ayala Healthcare Holdings, Inc. (AC Health) is a wholly-owned subsidiary of the Ayala Corporation that aims to provide every Filipino accessible, affordable, and quality healthcare. Its portfolio includes Generika Drugstore, the pioneer in generic retail pharmacies, IE Medica and MedEthix, a major pharmaceutical importer and distributor, Healthway Medical Network, a network of multi-specialty clinics, ambulatory centers, and full-service hospitals, and KonsultaMD, a healthcare aggregator app that offers online consultations, medicine delivery, and clinic and diagnostic booking. Through its three pillars—pharma, hospitals and clinics, and digital health—AC Health creates a seamless and integrated healthcare ecosystem for the Filipino patient.

For information:

Rafa Abaya

Email: abaya.arg@achealth.com.ph

St. Joseph Drug

St. Joseph Drug (SJD) is one of the most trusted regional drugstore chains in the country today, committed to providing a wide range of high quality, safe, affordable pharmaceutical and health essential products and innovative, reliable pharmacy services. Founded as a family-owned business that originated in Dagupan City, Pangasinan, it has now evolved into 112 branches serving valued customers across North Luzon for the past 65 years. Guided by its core values and propelled by its vision and mission, the company advocates to make a significant impact on the overall health and wellness of the communities and families it serves.

For information:

Vicky T. Ugto

Email: vtugto@stjosephdrug.com